WO2003049681A3 - Synthesis of 4,5-dihydro-pyrazolo [3,4-c] pyrid-2-ones - Google Patents

Synthesis of 4,5-dihydro-pyrazolo [3,4-c] pyrid-2-ones Download PDF

Info

Publication number
WO2003049681A3
WO2003049681A3 PCT/US2002/038559 US0238559W WO03049681A3 WO 2003049681 A3 WO2003049681 A3 WO 2003049681A3 US 0238559 W US0238559 W US 0238559W WO 03049681 A3 WO03049681 A3 WO 03049681A3
Authority
WO
WIPO (PCT)
Prior art keywords
pyrid
pyrazolo
dihydro
ones
synthesis
Prior art date
Application number
PCT/US2002/038559
Other languages
French (fr)
Other versions
WO2003049681A2 (en
Inventor
Jiacheng Zhou
Lynette M Oh
Philip Ma
Hui-Yin Li
Pasquale N Confalone
Original Assignee
Bristol Myers Squibb Co
Jiacheng Zhou
Lynette M Oh
Philip Ma
Hui-Yin Li
Pasquale N Confalone
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co, Jiacheng Zhou, Lynette M Oh, Philip Ma, Hui-Yin Li, Pasquale N Confalone filed Critical Bristol Myers Squibb Co
Priority to MXPA04005508A priority Critical patent/MXPA04005508A/en
Priority to KR10-2004-7008884A priority patent/KR20040073467A/en
Priority to HU0500109A priority patent/HUP0500109A3/en
Priority to JP2003550732A priority patent/JP2005511712A/en
Priority to BR0214845-5A priority patent/BR0214845A/en
Priority to IL16195502A priority patent/IL161955A0/en
Priority to AU2002346624A priority patent/AU2002346624A1/en
Priority to EP02784699A priority patent/EP1467984A4/en
Publication of WO2003049681A2 publication Critical patent/WO2003049681A2/en
Publication of WO2003049681A3 publication Critical patent/WO2003049681A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D211/84—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
    • C07D211/86—Oxygen atoms
    • C07D211/88—Oxygen atoms attached in positions 2 and 6, e.g. glutarimide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D211/84—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
    • C07D211/86—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

A novel process and intermediates thereof for making 4,5-dihydro-pyrazolo[3,4-c]pyrid-2-ones of the type shown below from appropriate phenyl hydrazines is described. These compounds are useful as factor Xa inhibitors.
PCT/US2002/038559 2001-12-10 2002-12-03 Synthesis of 4,5-dihydro-pyrazolo [3,4-c] pyrid-2-ones WO2003049681A2 (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
MXPA04005508A MXPA04005508A (en) 2001-12-10 2002-12-03 Synthesis of 4,5-dihydro-pyrazolo [3,4-c] pyrid-2-ones.
KR10-2004-7008884A KR20040073467A (en) 2001-12-10 2002-12-03 Synthesis of 4,5-Dihydro-Pyrazolo[3,4-c]Pyrid-2-Ones
HU0500109A HUP0500109A3 (en) 2001-12-10 2002-12-03 Synthesis of 4,5-dihydro-pyrazolo[3,4-c]pyrid-2-ones
JP2003550732A JP2005511712A (en) 2001-12-10 2002-12-03 Synthesis of 4,5-dihydro-pyrazolo [3,4-c] pyrid-2-one
BR0214845-5A BR0214845A (en) 2001-12-10 2002-12-03 Synthesis of 4,5-dihydro-pyrazolo [3,4-c] pyrid-2-ones
IL16195502A IL161955A0 (en) 2001-12-10 2002-12-03 A process for preparing 5-dihydro-pyrazolo Ä3,4-cÜpyrid-2-one derivatives
AU2002346624A AU2002346624A1 (en) 2001-12-10 2002-12-03 Synthesis of 4,5-dihydro-pyrazolo [3,4-c] pyrid-2-ones
EP02784699A EP1467984A4 (en) 2001-12-10 2002-12-03 Synthesis of 4,5-dihydro-pyrazolo (3,4-c) pyrid-2-ones

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33908501P 2001-12-10 2001-12-10
US60/339,085 2001-12-10

Publications (2)

Publication Number Publication Date
WO2003049681A2 WO2003049681A2 (en) 2003-06-19
WO2003049681A3 true WO2003049681A3 (en) 2003-09-18

Family

ID=23327425

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/038559 WO2003049681A2 (en) 2001-12-10 2002-12-03 Synthesis of 4,5-dihydro-pyrazolo [3,4-c] pyrid-2-ones

Country Status (13)

Country Link
US (3) US6919451B2 (en)
EP (1) EP1467984A4 (en)
JP (1) JP2005511712A (en)
KR (1) KR20040073467A (en)
CN (1) CN1639147A (en)
AU (1) AU2002346624A1 (en)
BR (1) BR0214845A (en)
HU (1) HUP0500109A3 (en)
IL (1) IL161955A0 (en)
MX (1) MXPA04005508A (en)
PL (1) PL371930A1 (en)
TW (2) TW200303201A (en)
WO (1) WO2003049681A2 (en)

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE439360T1 (en) 2001-09-21 2009-08-15 Bristol Myers Squibb Co LACTAM-CONTAINING COMPOUNDS AND THEIR DERIVATIVES AS FACTOR XA INHIBITORS
TWI320039B (en) 2001-09-21 2010-02-01 Lactam-containing compounds and derivatives thereof as factor xa inhibitors
US20070203178A1 (en) * 2004-09-28 2007-08-30 Malley Mary F Crystalline solvates of apixaban
US7304157B2 (en) 2004-09-28 2007-12-04 Bristol-Myers Squibb Company Efficient synthesis of 4,5-dihydro-pyrazolo[3,4-c]pyrid-2-ones
US20060069085A1 (en) * 2004-09-28 2006-03-30 Rulin Zhao Preparation of 4,5-dihydro-pyrazolo[3,4-c]pyrid-2-ones
CN101065379B (en) * 2004-09-28 2011-05-11 布里斯托尔-迈尔斯斯奎布公司 Process for preparing 4,5-dihydro-pyrazolo [3,4-c] pyrid-2-ones
US7396932B2 (en) * 2004-09-28 2008-07-08 Bristol-Myers Squibb Company Process for preparing 4,5-dihydro-pyrazolo[3,4-c]pyrid-2-ones
DE102006025315A1 (en) * 2006-05-31 2007-12-06 Bayer Healthcare Ag Tetrahydro-pyrrolopyridine, tetrahydro-pyrazolopyridine, tetrahydro-imidazopyridine and tetrahydro-triazolopyridine derivatives and their use
DE102007028406A1 (en) 2007-06-20 2008-12-24 Bayer Healthcare Ag Substituted oxazolidinones and their use
DE102007028407A1 (en) 2007-06-20 2008-12-24 Bayer Healthcare Ag Substituted oxazolidinones and their use
DE102007028319A1 (en) 2007-06-20 2008-12-24 Bayer Healthcare Ag Substituted oxazolidinones and their use
DE102007032344A1 (en) * 2007-07-11 2009-01-15 Bayer Healthcare Ag Prodrug derivatives of 1- (4-methoxyphenyl) -7-oxo-6- [4- (2-oxopiperidin-1-yl) phenyl] -4,5,6,7-tetrahydro-1H-pyrazolo [3,4 -c] pyridine-3-carboxamide
US20090076069A1 (en) * 2007-09-14 2009-03-19 Protia, Llc Deuterium-enriched apixaban
US20100130543A1 (en) * 2008-09-15 2010-05-27 Auspex Pharmaceuticals, Inc. Pyrazole carboxamide inhibitors of factor xa
CN101967145B (en) * 2010-09-09 2012-07-04 华东理工大学 Method for preparing antithrombotic medicament apixaban
ITMI20111047A1 (en) * 2011-06-10 2012-12-11 Dipharma Francis Srl CRYSTAL FORM OF APIXABAN
ITMI20111135A1 (en) * 2011-06-22 2012-12-23 Dipharma Francis Srl PROCEDURE FOR THE PREPARATION OF APIXABAN
US8884016B2 (en) 2011-06-10 2014-11-11 Dipharma Francis S.R.L. Apixaban preparation process
CN103242310A (en) * 2012-02-10 2013-08-14 苏州迈泰生物技术有限公司 Pyrazolo pyridone compound and its application in preparation of anticoagulant
CN102675314A (en) * 2012-06-14 2012-09-19 南京正科制药有限公司 Method for synthesizing apixaban
CN103626759B (en) * 2012-08-24 2015-10-21 上海医药工业研究院 A kind of preparation method of intermediate of Eliquis
WO2014072884A1 (en) * 2012-11-12 2014-05-15 Alembic Pharmaceuticals Limited Process for the synthesis of apixaban
CZ304846B6 (en) 2012-11-13 2014-12-03 Zentiva, K.S. Process for preparing APIXABAN
EP2945946B1 (en) 2013-01-17 2017-07-12 Glenmark Pharmaceuticals Limited Process for the preparation and purification of apixaban
CN103539795A (en) * 2013-03-18 2014-01-29 齐鲁制药有限公司 Apixaban polymorph and preparation method thereof
CN104109165A (en) * 2013-04-19 2014-10-22 四川海思科制药有限公司 4,5-dihydro-pyrazolo[3,4-c]pyrid-2-one derivatives, and preparation method and application thereof
CZ2013305A3 (en) 2013-04-23 2014-11-05 Zentiva, K.S. Novel crystalline forms of APIXABAN and process of their preparation
US20160113912A1 (en) 2013-06-18 2016-04-28 Cadila Healthcare Limited An improved process for the preparation of apixaban and intermediates thereof
CN103739541B (en) * 2014-01-07 2016-01-20 上海现代制药股份有限公司 The preparation method of 5,6-dihydro-3-(4-morpholinyl)-1-[4-(2-oxo-piperidino) phenyl]-2 (1H)-pyridones
IN2014MU00197A (en) 2014-01-21 2015-08-28 Wanbury Ltd
CN103896940B (en) * 2014-03-25 2016-02-03 江苏弘和药物研发有限公司 A kind of synthetic method of Eliquis
CN103923080B (en) * 2014-04-04 2016-06-22 苏州景泓生物技术有限公司 A kind of method preparing antithrombotic reagent Eliquis
CN104045637B (en) * 2014-04-18 2016-04-06 河北科技大学 A kind of preparation method of Eliquis
WO2015162551A1 (en) 2014-04-21 2015-10-29 Mylan Laboratories Ltd Process for the preparation of apixaban
WO2015176625A1 (en) * 2014-05-22 2015-11-26 南京明德新药研发股份有限公司 HYDRAZINE COMPOUND AS BLOOD COAGULATION FACTOR Xa INHIBITOR
WO2015177801A1 (en) * 2014-05-23 2015-11-26 Symed Labs Limited Novel process for the preparation of a lactam-containing compound
HU231122B1 (en) 2014-08-06 2020-11-30 Egis Gyógyszergyár Zrt Process for the preparation of apixaban
AU2015301891B2 (en) 2014-08-11 2019-12-05 Angion Biomedica Corporation Cytochrome P450 inhibitors and uses thereof
CN104311555B (en) * 2014-09-19 2016-04-20 广东东阳光药业有限公司 Pyrazolo piperidone compounds and composition thereof and purposes
CN104277040B (en) * 2014-09-19 2016-04-20 广东东阳光药业有限公司 Containing acyl piperazine ketone substituent pyrazolo piperidone compounds and composition thereof and purposes
CN104277037B (en) * 2014-09-19 2015-12-09 广东东阳光药业有限公司 Containing whorled pyrazolo piperidone compounds and composition thereof and purposes
CN104311558B (en) * 2014-09-19 2016-06-01 广东东阳光药业有限公司 Pyrazoles containing hexanaphthene substituting group piperidone compounds and composition thereof and purposes
CN104327074B (en) * 2014-09-19 2016-01-06 广东东阳光药业有限公司 Containing lactan substituent pyrazolo piperidone compounds and composition thereof and purposes
EP3098221B1 (en) * 2014-10-15 2017-12-06 F.I.S.- Fabbrica Italiana Sintetici S.p.A. Process for preparing apixaban form n-1
WO2016067308A1 (en) * 2014-10-28 2016-05-06 Jubilant Generics Limited (Formerly Jubilant Life Sciences Division) Process for the preparation of apixaban and intermediates thereof
HU230991B1 (en) * 2014-11-19 2019-08-28 Egis Gyógyszergyár Zrt. Intermediate and process for the preparation of apixaban
US9603846B2 (en) 2014-11-25 2017-03-28 Cadila Healthcare Limited Process for the preparation of apixaban
CN107531631B (en) 2014-12-31 2021-09-03 安吉昂生物医药公司 Methods and agents for treating diseases
CN104892601B (en) * 2015-06-09 2017-09-19 江苏中邦制药有限公司 A kind of preparation method of antithrombotic reagent Eliquis
EP3064497A1 (en) * 2015-07-20 2016-09-07 F.I.S.- Fabbrica Italiana Sintetici S.p.A. Dimer impurities of apixaban and method to remove them
CN106632312B (en) * 2015-11-03 2019-05-14 上海医药工业研究院 A kind of related substance of Eliquis, intermediate, preparation method and applications
CN105732618A (en) * 2016-02-02 2016-07-06 扬州大学 Method for synthesizing 4-(2-oxo-piperidine-1-yl)aryl-carboxylic ethyl ester compound
EP3228619B1 (en) * 2016-04-04 2020-07-29 Zaklady Farmaceutyczne Polpharma SA Process for the preparation of apixaban
US10077263B2 (en) * 2016-04-29 2018-09-18 Optimus Drugs Private Limited Process for the preparation of Apixaban
CN106117200B (en) * 2016-06-27 2018-02-02 张士伟 Prevention or the preparation method for the treatment of joint replacement phlebothrombosis medicine Eliquis
WO2018049214A1 (en) 2016-09-09 2018-03-15 Incyte Corporation Pyrazolopyridine derivatives as hpk1 modulators and uses thereof for the treatment of cancer
TW201811799A (en) 2016-09-09 2018-04-01 美商英塞特公司 Pyrazolopyrimidine compounds and uses thereof
AR109596A1 (en) 2016-09-09 2018-12-26 Incyte Corp PIRAZOLOPIRIDINE COMPOUNDS AND THEIR USES
CN107434806A (en) * 2016-12-09 2017-12-05 陕西科技大学 γ crystal formation solid matters of a kind of Eliquis carboxylic acid derivates and preparation method thereof and purposes
US20180228786A1 (en) 2017-02-15 2018-08-16 Incyte Corporation Pyrazolopyridine compounds and uses thereof
US10722495B2 (en) 2017-09-08 2020-07-28 Incyte Corporation Cyanoindazole compounds and uses thereof
CN107955002B (en) * 2017-12-27 2019-12-24 上海博志研新药物技术有限公司 Preparation method of apixaban and intermediate thereof
CN107955003A (en) * 2017-12-28 2018-04-24 河北常山生化药业股份有限公司 The sweep-out method of specific impurities S4 in a kind of 2 building-up process of Eliquis intermediate
CN107936015B (en) * 2017-12-28 2020-05-12 浙江天宇药业股份有限公司 Synthesis method of N-1 crystal form Apixaban
US10745388B2 (en) 2018-02-20 2020-08-18 Incyte Corporation Indazole compounds and uses thereof
WO2019164847A1 (en) 2018-02-20 2019-08-29 Incyte Corporation Indazole compounds and uses thereof
MD3755703T2 (en) 2018-02-20 2022-10-31 Incyte Corp N-(phenyl)-2-(phenyl)pyrimidine-4-carboxamide derivatives and related compounds as HPK1 inhibitors for treating cancer
US11299473B2 (en) 2018-04-13 2022-04-12 Incyte Corporation Benzimidazole and indole compounds and uses thereof
US10899755B2 (en) 2018-08-08 2021-01-26 Incyte Corporation Benzothiazole compounds and uses thereof
TW202028207A (en) 2018-09-25 2020-08-01 美商英塞特公司 Pyrazolopyrimidine compounds and uses thereof
KR102188341B1 (en) 2018-10-24 2020-12-08 하나제약 주식회사 Method for Preparation of Apixaban
KR20220059480A (en) 2019-08-06 2022-05-10 인사이트 코포레이션 HPK1 inhibitor in solid form
CN111253392B (en) * 2019-12-17 2021-06-11 哈尔滨珍宝制药有限公司 Method for preparing apixaban
CN113214142B (en) * 2020-01-21 2024-01-30 浙江九洲药业股份有限公司 Apixaban intermediate and preparation method thereof
JP2022022550A (en) * 2020-06-26 2022-02-07 ダイト株式会社 Novel production method for apixaban
CN112142736B (en) * 2020-10-29 2021-08-10 怀化学院 Preparation method of apixaban impurity 1

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4409228A (en) * 1979-06-21 1983-10-11 Sanofi Andrexiant aminopiperidines intermediates thereto and drugs containing same

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1140941T1 (en) 1998-12-23 2005-04-30 Bristol-Myers Squibb Pharma Company Nitrogen containing heterobicycles as factor xa inhibitors
US6329527B1 (en) 1999-10-21 2001-12-11 Bristol-Myers Squibb Pharma Company Synthesis of 1,3,5-trisubstituted pyrazoles
TWI320039B (en) 2001-09-21 2010-02-01 Lactam-containing compounds and derivatives thereof as factor xa inhibitors
ATE439360T1 (en) 2001-09-21 2009-08-15 Bristol Myers Squibb Co LACTAM-CONTAINING COMPOUNDS AND THEIR DERIVATIVES AS FACTOR XA INHIBITORS
US20060069085A1 (en) * 2004-09-28 2006-03-30 Rulin Zhao Preparation of 4,5-dihydro-pyrazolo[3,4-c]pyrid-2-ones
US7396932B2 (en) * 2004-09-28 2008-07-08 Bristol-Myers Squibb Company Process for preparing 4,5-dihydro-pyrazolo[3,4-c]pyrid-2-ones
US7304157B2 (en) * 2004-09-28 2007-12-04 Bristol-Myers Squibb Company Efficient synthesis of 4,5-dihydro-pyrazolo[3,4-c]pyrid-2-ones

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4409228A (en) * 1979-06-21 1983-10-11 Sanofi Andrexiant aminopiperidines intermediates thereto and drugs containing same

Also Published As

Publication number Publication date
EP1467984A2 (en) 2004-10-20
PL371930A1 (en) 2005-07-11
HUP0500109A2 (en) 2005-05-30
US20050245566A1 (en) 2005-11-03
KR20040073467A (en) 2004-08-19
CN1639147A (en) 2005-07-13
TW200738672A (en) 2007-10-16
WO2003049681A2 (en) 2003-06-19
BR0214845A (en) 2004-12-07
US6919451B2 (en) 2005-07-19
TW200303201A (en) 2003-09-01
AU2002346624A1 (en) 2003-06-23
US20030181466A1 (en) 2003-09-25
HUP0500109A3 (en) 2007-08-28
JP2005511712A (en) 2005-04-28
EP1467984A4 (en) 2005-12-07
MXPA04005508A (en) 2004-12-06
US7153960B2 (en) 2006-12-26
US20070027186A1 (en) 2007-02-01
IL161955A0 (en) 2005-11-20

Similar Documents

Publication Publication Date Title
WO2003049681A3 (en) Synthesis of 4,5-dihydro-pyrazolo [3,4-c] pyrid-2-ones
WO2007001385A3 (en) Process for preparing 4,5-dihydro-pyrazolo [3,4-c] pyrid-2-ones
WO2006135425A3 (en) Preparation of 4,5-dihydro-pyrazolo[3,4-c]pyrid-2-ones
AU3662799A (en) Processes for the synthesis of oligomeric compounds
AU2002226093A1 (en) Process for the manufacture of novel, inexpensive radio frequency identificationdevices
AU1601100A (en) Improved processes for the synthesis of oligomeric compounds
AU6255301A (en) Serine protease inhibitors
WO2006036926A3 (en) Efficient synthesis of 4,5-dihydro-pyrazolo[3,4-c]pyrid-2-ones
EP1380564A4 (en) Binaphtol derivative and process for producing the same
AU2002235326A1 (en) Processes for large scale production of tetrapyrroles
AU2003279186A1 (en) Process of purifying phosphoramidites
AU2273599A (en) Production of polyamides by reactive distillation
AU2002367752A1 (en) Substituted 5-membered polycyclic compounds useful for selective inhibition of the coagulation cascade
AU1651001A (en) Difluoromethyltriazolone compounds, use of the same and intermediates for the production thereof
WO2002024690A3 (en) Efficient process for the preparation of a factor xa inhibitor
AU2001277728A1 (en) Biphenylcarboxamidoisoindoline compounds, processes for the preparation of the same and intermediates for the synthesis thereof
TW200626596A (en) Preparation of 4 5-dihydro-pyrazolo[3, 4-c]pyrid-2-ones
AU2002335992A1 (en) Process for the production of ascopyrone p
TW200626597A (en) Efficient synthesis of 4, 5-dihydro-pyrazolo [3, 4-c]pyrid-2-ones
AU2001292236A1 (en) 5-phenylbenzylamine compounds, process for their production and intermediates for their synthesis
TW200626595A (en) Process for preparing 4, 5-dihydro-pyrazolo [3, 4-c]pyrid-2-ones
AU2001262240A1 (en) Process for the production of 2,2,6-trimethylcyclohexane-1,4-dione
AU2159997A (en) Process for producing intermediate compounds for the production of factor xa inhibitors
HUP0001700A2 (en) Process for the production of 8-cyclopentyl-6-ethyl-3-[substituted]-5,8-dihydro-4h-1,2,3a,7,8-pentaaza-as-indacenes and intermediates useful therein
AU2002352424A1 (en) Solution-phase process for the manufacture of decapeptide

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 161955

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 01335/DELNP/2004

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2002784699

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 10496680

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 20028242920

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: PA/a/2004/005508

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2002346624

Country of ref document: AU

Ref document number: 1020047008884

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 2003550732

Country of ref document: JP

WWP Wipo information: published in national office

Ref document number: 2002784699

Country of ref document: EP